PSMB5 Cancer Research Results

PSMB5, proteasome subunit beta type-5: Click to Expand ⟱
Source:
Type:
PSMB5 is a gene that provides instructions for making a protein called proteasome subunit beta type-5. This protein is a part of the larger proteasome complex, which helps break down unneeded or damaged proteins in the cell.

PSMB5 is a key component of the proteasome complex whose altered expression or mutation plays an important role in cancer biology. In hematologic malignancies—especially multiple myeloma—elevated levels or mutant forms of PSMB5 are associated with resistance to proteasome inhibitors and poorer outcomes. In solid tumors, increased proteasome activity via PSMB5 may support tumor cell survival under proteotoxic and metabolic stress, although its prognostic value can be more variable.


Scientific Papers found: Click to Expand⟱
746- Bor,    Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope
- Review, NA, NA
eff↑, newly developed boron-containing compounds have already demonstrated highly promising activities
*toxicity↓, Boronic acid/ester has been successfully incorporated into cancer treatments and therapy mainly due to its remarkable oxophilicity and low toxicity levels in the body
ROS↑, can trigger tumour microenvironmental abnormalities such as high levels of reactive oxygen species (ROS) and overexpressed enzymes
LAT↓, boron accumulation were observed to counterpart LAT-1 expression in a bone metastasis model of breast cancer
AntiCan↑, high concentration of boron in males reduces the probability of prostate cancer by 54% compared to males with low boron concentrations
AR↓, bortezomib
PSMB5↓, bortezomib
IGF-1↓, insulin-like growth factor 1 (IGF-1) in tumours was markedly reduced by boric acid.
PSA↓, exposure to both low-and high-dose boron supplementation, prostate-specific antigen (PSA) levels dropped by an average of 87%, while tumour size declined by an average of 31.5%
TumVol↓,
eff↑, phenylboronic acid is a more potent inhibitor than boric acid in targeting metastatic and proliferative properties of prostate cancer cells
Rho↓, RhoA, Rac1
Cdc42↓,
Ca+2↓, ER Ca+2 depletion occurred after the treatment of DU-145 prostate cancer cells with the physiological concentrations of boric acid
eff↑, boric acid (BA), sodium pentaborate pentahydrate (NaB), and sodium perborate tetrahydrate (SPT) against SCLC cell line using DMS-114 cells

415- CUR,    Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis
- vitro+vivo, BC, MDA-MB-231
PSMB5↓,
CT-I↓,
miR-142-3p↑,
EP300↓, P300


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

LAT↓, 1,   PSMB5↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

EP300↓, 1,   IGF-1↓, 1,   miR-142-3p↑, 1,  

Migration ⓘ

Ca+2↓, 1,   Cdc42↓, 1,   Rho↓, 1,  

Immune & Inflammatory Signaling ⓘ

PSA↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

CT-I↓, 1,   eff↑, 3,  

Clinical Biomarkers ⓘ

AR↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   TumVol↓, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: PSMB5, proteasome subunit beta type-5
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:649  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page